Precision Medicine in Oncology®

Matthew P. Goetz, MD, Mayo Clinic, discusses the use of circulating tumor DNA in the phase III MONARCH-3 trial in hormone receptor–positive, HER2-negative breast cancer.

R. Steven Paulson, MD, discusses the utility of liquid biopsies versus tissue biopsies.

Mark E. Robson, MD, provides a snapshot of the precision focus in breast cancer, as well as the emergence of biosimilars in the field.

Innovative clinical trials designed to exploit the explosion of data on the drivers of cancer are demonstrating value as tools to explore potential signals of efficacy across tumor types, according to oncology experts. These studies have become a feature of the drug discovery landscape in oncology and are likely to remain part of the fabric of clinical research in the genomic era.

Single-agent vorasidenib or ivosidenib led to brain penetrance and 2-hydroxyglutarate suppression in patients with low-grade glioma who harbor IDH1 mutations.

Joseph A. Sparano, MD, discusses using gene expression profiles as a means to guide therapy in breast cancer.

Updated guidelines from the United States Preventive Services Task Force on BRCA1/2 genetic testing recommend risk assessment, counseling, and genetic test-ing for women who meet certain criteria but fall short of encompassing important groups of individuals who are at risk for developing BRCA1/2 mutation–driven disease

In the ongoing search for novel immunotherapies that might rival or surpass the efficacy of immune checkpoint inhibitors, drugs targeting IDO1—a key enzyme in tryptophan metabolism—have been a major focus in recent years.

James P. Stevenson, MD, discusses available biomarker-driven therapies in non–small cell lung cancer, as well as rarer biomarkers under clinical investigation.